UniCycive Therapeutics Inc (UNCY)

[Whalatane]

Seth

Cash Position: As of March 31, 2024, cash and cash equivalents totaled $48.9 million

Assume they are down to $40m cash now with a current market cap of $29m .

A company with $40m cash on hand is currently valued in the market at $29m ??

Even if this OLC trial is a complete failure , they still have Orphan drug designation for their delayed graft function drug UNI -494

This is a small Co . Easy for aggressive short hedge funds to push the PPS around floating things like " they are fishing for results they want ,which is why they increased the number in the trial "

Its a tolerability trial . Patients either adjusted to the med ...or they didn't and dropped out .
Data any day now ...which I've been saying for about a week ..:--)

Kiwi